Rachel H. Limpert

Rachel H. Limpert

Auto-generated profile, based on publicly available information

Rachel H. Limpert

Department of Anesthesiology (G.S., R.H.L., B.J.L., J.K.F.), Medical College of Wisconsin, Milwaukee

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
GSGopika SenthilKumar
Gopika SenthilKumar
ZZZachary Zirgibel
Zachary Zirgibel
KCKatie E. Cohen
Katie E. Cohen
BKBoran Katunaric
Boran Katunaric
AJAlyssa M. Jobe
Alyssa M. Jobe
JFJulie K. Freed
Julie K. Freed
Ceramides, a group of biologically active sphingolipids, have been described as the new cholesterol given strong evidence linking high plasma ceramide with endothelial damage, risk for early adverse cardiovascular events, and development of cardiometabolic disease. This relationship has sparked great interest in investigating therapeutic targets with the goal of suppressing ceramide formation. However, the growing data challenge this paradigm of ceramide as solely eliciting detrimental effects to the cardiovascular system. Studies show that ceramides are necessary for maintaining proper endothelial redox states, mechanosensation, and membrane integrity. Recent work in preclinical models and isolated human microvessels highlights that the loss of ceramide formation can in fact propagate vascular endothelial dysfunction. Here, we delve into these conflicting findings to evaluate how ceramide may be capable of exerting both beneficial and damaging effects within the vascular endothelium. We propose a unifying theory that while basal levels of ceramide in response to physiological stimuli are required for the production of vasoprotective metabolites such as S1P (sphingosine-1-phosphate), the chronic accumulation of ceramide can promote activation of pro-oxidative stress pathways in endothelial cells. Clinically, the evidence discussed here highlights the potential challenges associated with therapeutic suppression of ceramide formation as a means of reducing cardiovascular disease risk.

1 August 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
GSGopika SenthilKumar
Gopika SenthilKumar
RLRachel H. Limpert
Rachel H. Limpert
BLBrian Lindemer
Brian Lindemer
JFJulie K. Freed
Julie K. Freed